Pub Date : 2024-11-10DOI: 10.3390/pathogens13110984
Esha Madhu Kapania, Rodrigo Cavallazzi
While rare, necrotizing pneumonia is a severe and potentially life-threatening manifestation of lung parenchyma infection. Initially documented in the 1940s, it was a significant contributor to mortality rates in both adults and children, with figures reaching up to 45%. Despite being a disease described in the literature for decades, data on the management of necrotizing pneumonia remain limited. Most available information comes from retrospective observational cohort studies. This article aims to provide a comprehensive summary of the existing literature on the subject.
{"title":"Necrotizing Pneumonia: A Practical Guide for the Clinician.","authors":"Esha Madhu Kapania, Rodrigo Cavallazzi","doi":"10.3390/pathogens13110984","DOIUrl":"10.3390/pathogens13110984","url":null,"abstract":"<p><p>While rare, necrotizing pneumonia is a severe and potentially life-threatening manifestation of lung parenchyma infection. Initially documented in the 1940s, it was a significant contributor to mortality rates in both adults and children, with figures reaching up to 45%. Despite being a disease described in the literature for decades, data on the management of necrotizing pneumonia remain limited. Most available information comes from retrospective observational cohort studies. This article aims to provide a comprehensive summary of the existing literature on the subject.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The impact of common respiratory virus infections on adults and older individuals in the community is unclear, excluding seasonal influenza viruses. We examined FilmArray® tests performed on 1828 children aged <10 years and 10,803 adults, including cases with few respiratory symptoms, between January 2021 and June 2024. Approximately 80% of the children tested positive for ≥1 viruses, while 9.5% of the adults tested positive mostly for severe acute respiratory syndrome corona virus-2 (SARS-CoV-2). Besides SARS-CoV-2 infection, 66 out of 97 patients (68.0%) aged >60 years with rhinovirus/enterovirus (RV/EV), respiratory syncytial virus (RSV), parainfluenza virus-3 (PIV-3), or human metapneumovirus (hMPV) infection required hospitalization, of whom seven died; 26 out of 160 patients (16.3%) aged <60 years required hospitalization mostly because of deterioration of bronchial asthma, with no reported deaths. In older patients with RV/EV infection, three with few respiratory symptoms died due to worsened heart failure. Although the frequency of common respiratory virus infections in older adults is low, it may be overlooked because of subclinical respiratory symptoms, and its clinical significance in worsening comorbidities in older adults should not be underestimated.
{"title":"Observational Study on the Clinical Reality of Community-Acquired Respiratory Virus Infections in Adults and Older Individuals.","authors":"Masayuki Nagasawa, Tomohiro Udagawa, Tomoyuki Kato, Ippei Tanaka, Ren Yamamoto, Hayato Sakaguchi, Yoshiyuki Sekikawa","doi":"10.3390/pathogens13110983","DOIUrl":"10.3390/pathogens13110983","url":null,"abstract":"<p><p>The impact of common respiratory virus infections on adults and older individuals in the community is unclear, excluding seasonal influenza viruses. We examined FilmArray® tests performed on 1828 children aged <10 years and 10,803 adults, including cases with few respiratory symptoms, between January 2021 and June 2024. Approximately 80% of the children tested positive for ≥1 viruses, while 9.5% of the adults tested positive mostly for severe acute respiratory syndrome corona virus-2 (SARS-CoV-2). Besides SARS-CoV-2 infection, 66 out of 97 patients (68.0%) aged >60 years with rhinovirus/enterovirus (RV/EV), respiratory syncytial virus (RSV), parainfluenza virus-3 (PIV-3), or human metapneumovirus (hMPV) infection required hospitalization, of whom seven died; 26 out of 160 patients (16.3%) aged <60 years required hospitalization mostly because of deterioration of bronchial asthma, with no reported deaths. In older patients with RV/EV infection, three with few respiratory symptoms died due to worsened heart failure. Although the frequency of common respiratory virus infections in older adults is low, it may be overlooked because of subclinical respiratory symptoms, and its clinical significance in worsening comorbidities in older adults should not be underestimated.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110981
Chukwunonso Onyilagha, Kaye Quizon, Dmytro Zhmendak, Ian El Kanoa, Thang Truong, Thanuja Ambagala, Alfonso Clavijo, Van Phan Le, Shawn Babiuk, Aruna Ambagala
African swine fever (ASF) is an economically devastating viral disease of pigs caused by the ASF virus (ASFV). The rapid global spread of ASF has increased the demand for ASF diagnostics to be readily available and accessible. No commercial ASF enzyme-linked immunosorbent assay (ELISA) kits are manufactured and licensed in North America. Here, we report the development of two serological diagnostic assays, a blocking ELISA (bELISA) based on ASFV glycoprotein p54 and an indirect ELISA (iELISA) based on ASFV glycoproteins p54 and p72. The assays showed high sensitivity and specificity and detected anti-ASFV antibodies in serum samples from experimentally infected animals as early as 8 days post-infection. The two assays were produced commercially (AsurDx™ bELISA and iELISA) and subjected to extensive validation. Based on data from a set of characterized reference sera, the prototype commercial assays, while maintaining 100.00% specificity, showed 97.67% (AsurDx™ bELISA) and 83.72% (AsurDx™ iELISA) sensitivity. Both prototype assays detected anti-ASFV antibodies in serum samples collected from pigs experimentally infected with multiple ASFV strains and field samples collected from sick, recovering, and vaccinated animals. The two commercially available assays can be used in routine ASF diagnostics, serological surveys, and for evaluating serological responses to ASF vaccine candidates.
{"title":"Development and Validation of an Indirect and Blocking ELISA for the Serological Diagnosis of African Swine Fever.","authors":"Chukwunonso Onyilagha, Kaye Quizon, Dmytro Zhmendak, Ian El Kanoa, Thang Truong, Thanuja Ambagala, Alfonso Clavijo, Van Phan Le, Shawn Babiuk, Aruna Ambagala","doi":"10.3390/pathogens13110981","DOIUrl":"10.3390/pathogens13110981","url":null,"abstract":"<p><p>African swine fever (ASF) is an economically devastating viral disease of pigs caused by the ASF virus (ASFV). The rapid global spread of ASF has increased the demand for ASF diagnostics to be readily available and accessible. No commercial ASF enzyme-linked immunosorbent assay (ELISA) kits are manufactured and licensed in North America. Here, we report the development of two serological diagnostic assays, a blocking ELISA (bELISA) based on ASFV glycoprotein p54 and an indirect ELISA (iELISA) based on ASFV glycoproteins p54 and p72. The assays showed high sensitivity and specificity and detected anti-ASFV antibodies in serum samples from experimentally infected animals as early as 8 days post-infection. The two assays were produced commercially (AsurDx<sup>™</sup> bELISA and iELISA) and subjected to extensive validation. Based on data from a set of characterized reference sera, the prototype commercial assays, while maintaining 100.00% specificity, showed 97.67% (AsurDx<sup>™</sup> bELISA) and 83.72% (AsurDx<sup>™</sup> iELISA) sensitivity. Both prototype assays detected anti-ASFV antibodies in serum samples collected from pigs experimentally infected with multiple ASFV strains and field samples collected from sick, recovering, and vaccinated animals. The two commercially available assays can be used in routine ASF diagnostics, serological surveys, and for evaluating serological responses to ASF vaccine candidates.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110978
Chrysoula Petrokilidou, Eleftherios Pavlou, Aristea Velegraki, Anna Simou, Ioanna Marsellou, Grigorios Filis, Ioannis D Bassukas, Georgios Gaitanis, Nikolaos Kourkoumelis
Candida auris, an emerging multidrug-resistant fungal pathogen, poses significant challenges in healthcare settings due to its high misidentification rate and resilience to treatments. Despite advancements in diagnostic tools, a gap remains in rapid, cost-effective identification methods that can differentiate C. auris from other Candida species, particularly on non-standard culture media. We used Raman spectroscopy to characterize C. auris grown on modified Dixon's agar (mDixon) and differentiated it from Candida albicans and Candida parapsilosis. Key Raman spectral markers at 1171 cm-1 and 1452 cm-1, linked to mannan and β-glucan composition, differentiated C. auris into two subgroups, A and B. Despite the spectral similarities of groups A and B with C. albicans and C. parapsilosis, respectively, all Candida species were distinguishable through principal component analysis (PCA). Additionally, this study is the first to demonstrate the distinct spectral signature of mDixon agar, achieved through spatially offset Raman spectroscopy (SORS), which enables accurate discrimination between the culture medium and fungal samples. The observed inter-individual variability within C. auris, coupled with the spectral overlap between C. auris subgroups and other Candida species, highlights a major challenge in differentiating closely related fungi due to their similar molecular composition. Enhancements in spectral resolution and further fluorescence minimization from the culture medium are needed to reliably detect the subtle biochemical differences within these species. Despite these challenges, the results underscore the potential of Raman spectroscopy as a real-time, non-destructive, and complementary tool for fungal pathogen identification.
白色念珠菌是一种新出现的具有多重耐药性的真菌病原体,由于其识别错误率高且对治疗具有抵抗力,给医疗机构带来了巨大挑战。尽管诊断工具取得了进步,但在快速、经济有效的鉴定方法方面仍存在差距,这些方法可以将白色念珠菌与其他念珠菌物种区分开来,尤其是在非标准培养基上。我们使用拉曼光谱鉴定了生长在改良狄克逊琼脂(mDixon)上的白色念珠菌,并将其与白念珠菌和副丝状念珠菌区分开来。尽管 A 组和 B 组分别与白念珠菌和副丝状念珠菌的光谱相似,但通过主成分分析(PCA),所有念珠菌都可以区分开来。此外,本研究还首次通过空间偏移拉曼光谱(SORS)展示了 mDixon 琼脂的独特光谱特征,从而能够准确区分培养基和真菌样本。所观察到的 C. auris 的个体间差异,以及 C. auris 亚群和其他念珠菌物种之间的光谱重叠,突出表明了由于分子组成相似而在区分近缘真菌时所面临的重大挑战。要想可靠地检测出这些物种内部微妙的生化差异,需要提高光谱分辨率并进一步减少培养基的荧光。尽管存在这些挑战,但研究结果凸显了拉曼光谱作为一种实时、非破坏性和补充性的真菌病原体鉴定工具的潜力。
{"title":"Characterization and Differentiation of <i>Candida auris</i> on Dixon's Agar Using Raman Spectroscopy.","authors":"Chrysoula Petrokilidou, Eleftherios Pavlou, Aristea Velegraki, Anna Simou, Ioanna Marsellou, Grigorios Filis, Ioannis D Bassukas, Georgios Gaitanis, Nikolaos Kourkoumelis","doi":"10.3390/pathogens13110978","DOIUrl":"10.3390/pathogens13110978","url":null,"abstract":"<p><p><i>Candida auris</i>, an emerging multidrug-resistant fungal pathogen, poses significant challenges in healthcare settings due to its high misidentification rate and resilience to treatments. Despite advancements in diagnostic tools, a gap remains in rapid, cost-effective identification methods that can differentiate <i>C. auris</i> from other <i>Candida</i> species, particularly on non-standard culture media. We used Raman spectroscopy to characterize <i>C. auris</i> grown on modified Dixon's agar (mDixon) and differentiated it from <i>Candida albicans</i> and <i>Candida parapsilosis</i>. Key Raman spectral markers at 1171 cm<sup>-1</sup> and 1452 cm<sup>-1</sup>, linked to mannan and β-glucan composition, differentiated <i>C. auris</i> into two subgroups, A and B. Despite the spectral similarities of groups A and B with <i>C. albicans</i> and <i>C. parapsilosis</i>, respectively, all <i>Candida</i> species were distinguishable through principal component analysis (PCA). Additionally, this study is the first to demonstrate the distinct spectral signature of mDixon agar, achieved through spatially offset Raman spectroscopy (SORS), which enables accurate discrimination between the culture medium and fungal samples. The observed inter-individual variability within <i>C. auris</i>, coupled with the spectral overlap between <i>C. auris</i> subgroups and other <i>Candida</i> species, highlights a major challenge in differentiating closely related fungi due to their similar molecular composition. Enhancements in spectral resolution and further fluorescence minimization from the culture medium are needed to reliably detect the subtle biochemical differences within these species. Despite these challenges, the results underscore the potential of Raman spectroscopy as a real-time, non-destructive, and complementary tool for fungal pathogen identification.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110982
Jeong-Won Kim, Ji-Soo Jeong, Jin-Hwa Kim, Chang-Yeop Kim, Eun-Hye Chung, So-Young Boo, Soo-Ha Lee, Je-Won Ko, Tae-Won Kim
The need for antibiotics in commercial laying hens is increasing owing to intensive farming systems. Amoxicillin trihydrate (AMX), an aminopenicillin β-lactam antibiotic, exerts broad bactericidal activity. However, its short half-life necessitates frequent administration to ensure efficacy, thus limiting its use. Herein, we investigated the effect of concurrent administration of bromhexine hydrochloride (BRM), a mucolytic agent, on AMX pharmacokinetics, performing a comparative pharmacokinetic analysis of AMX administration alone and in combination with BRM. AMX (50 mg/kg) was administered by oral gavage once daily for three days alone or in combination with 10 mg/kg BRM. Plasma and egg samples were collected to evaluate pharmacokinetic profiles and egg residues. The area under the curve and maximum plasma concentration values were significantly higher in the AMX + BRM group than the AMX only group. However, there were no significant differences in AMX half-life in the elimination phase (T1/2), elimination rate constant (kel), or apparent clearance (CL/F) values. In the egg residue study, the withdrawal period for AMX was 5 days in both groups, with no significant difference when using the maximum residue limit (MRL) of 10 μg/kg. The concentration of BRM in the eggs remained at 100 μg/kg up to the fourth day following drug administration. Conclusion: These results confirmed that BRM co-administration increased systemic exposure to AMX, with a negligible residual impact of amoxicillin in eggs.
{"title":"Comparative Pharmacokinetics and Egg Residues of Amoxicillin, Single and in Combination with Bromhexine, in Laying Hens.","authors":"Jeong-Won Kim, Ji-Soo Jeong, Jin-Hwa Kim, Chang-Yeop Kim, Eun-Hye Chung, So-Young Boo, Soo-Ha Lee, Je-Won Ko, Tae-Won Kim","doi":"10.3390/pathogens13110982","DOIUrl":"10.3390/pathogens13110982","url":null,"abstract":"<p><p>The need for antibiotics in commercial laying hens is increasing owing to intensive farming systems. Amoxicillin trihydrate (AMX), an aminopenicillin β-lactam antibiotic, exerts broad bactericidal activity. However, its short half-life necessitates frequent administration to ensure efficacy, thus limiting its use. Herein, we investigated the effect of concurrent administration of bromhexine hydrochloride (BRM), a mucolytic agent, on AMX pharmacokinetics, performing a comparative pharmacokinetic analysis of AMX administration alone and in combination with BRM. AMX (50 mg/kg) was administered by oral gavage once daily for three days alone or in combination with 10 mg/kg BRM. Plasma and egg samples were collected to evaluate pharmacokinetic profiles and egg residues. The area under the curve and maximum plasma concentration values were significantly higher in the AMX + BRM group than the AMX only group. However, there were no significant differences in AMX half-life in the elimination phase (T<sub>1/2</sub>), elimination rate constant (k<sub>el</sub>), or apparent clearance (CL/F) values. In the egg residue study, the withdrawal period for AMX was 5 days in both groups, with no significant difference when using the maximum residue limit (MRL) of 10 μg/kg. The concentration of BRM in the eggs remained at 100 μg/kg up to the fourth day following drug administration. Conclusion: These results confirmed that BRM co-administration increased systemic exposure to AMX, with a negligible residual impact of amoxicillin in eggs.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110980
Po-Yuan Ke, Chau-Ting Yeh
Many types of RNA viruses, including the hepatitis C virus (HCV), activate autophagy in infected cells to promote viral growth and counteract the host defense response. Autophagy acts as a catabolic pathway in which unnecessary materials are removed via the lysosome, thus maintaining cellular homeostasis. The HCV non-structural 5A (NS5A) protein is a phosphoprotein required for viral RNA replication, virion assembly, and the determination of interferon (IFN) sensitivity. Recently, increasing evidence has shown that HCV NS5A can induce autophagy to promote mitochondrial turnover and the degradation of hepatocyte nuclear factor 1 alpha (HNF-1α) and diacylglycerol acyltransferase 1 (DGAT1). In this review, we summarize recent progress in understanding the detailed mechanism by which HCV NS5A triggers autophagy, and outline the physiological significance of the balance between host-virus interactions.
{"title":"Functional Role of Hepatitis C Virus NS5A in the Regulation of Autophagy.","authors":"Po-Yuan Ke, Chau-Ting Yeh","doi":"10.3390/pathogens13110980","DOIUrl":"10.3390/pathogens13110980","url":null,"abstract":"<p><p>Many types of RNA viruses, including the hepatitis C virus (HCV), activate autophagy in infected cells to promote viral growth and counteract the host defense response. Autophagy acts as a catabolic pathway in which unnecessary materials are removed via the lysosome, thus maintaining cellular homeostasis. The HCV non-structural 5A (NS5A) protein is a phosphoprotein required for viral RNA replication, virion assembly, and the determination of interferon (IFN) sensitivity. Recently, increasing evidence has shown that HCV NS5A can induce autophagy to promote mitochondrial turnover and the degradation of hepatocyte nuclear factor 1 alpha (HNF-1α) and diacylglycerol acyltransferase 1 (DGAT1). In this review, we summarize recent progress in understanding the detailed mechanism by which HCV NS5A triggers autophagy, and outline the physiological significance of the balance between host-virus interactions.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110976
Tobias Jakobsson, Pär Comstedt, Sven Bergström, Johan Normark
Lyme disease is a vector-borne illness caused by spirochetes belonging to the Borrelia burgdorferi species group. These bacteria employ several mechanisms to survive within the vertebrate host, including evasion of the complement system. In this study, we examine the protection against human serum killing by the binding of host complement regulators C4b-binding protein (C4BP) and factor H (FH) to the bacterial surface of B. burgdorferi. Via serum depletion of isolated complement regulators, we found that the absence of C4BP did not alter the survival of B. burgdorferi strain B31; however, the removal of FH increased the sensitivity of this strain to human serum as previously described. The B. garinii seabird-isolated strain Far04, on the other hand, did not bind any complement regulators of human origin and was serum-sensitive, indicating its special host species specificity.
莱姆病是一种病媒传播疾病,由博氏螺旋体引起。这些细菌利用多种机制在脊椎动物宿主体内生存,包括逃避补体系统。在这项研究中,我们研究了宿主补体调节因子 C4b 结合蛋白(C4BP)和因子 H(FH)与布氏杆菌细菌表面的结合对人类血清杀灭的保护作用。通过对分离的补体调节因子进行血清耗竭,我们发现 C4BP 的缺失不会改变 B. burgdorferi 菌株 B31 的存活;然而,如前所述,FH 的去除会增加该菌株对人类血清的敏感性。另一方面,从海鸟中分离出来的 B. garinii 菌株 Far04 没有结合任何来源于人类的补体调节因子,并且对血清敏感,这表明它具有特殊的宿主物种特异性。
{"title":"Survival of <i>Borrelia burgdorferi</i> Strain B31 in Human Serum Is Not Dependent on C4BP Binding to the Bacterial Surface.","authors":"Tobias Jakobsson, Pär Comstedt, Sven Bergström, Johan Normark","doi":"10.3390/pathogens13110976","DOIUrl":"10.3390/pathogens13110976","url":null,"abstract":"<p><p>Lyme disease is a vector-borne illness caused by spirochetes belonging to the <i>Borrelia burgdorferi</i> species group. These bacteria employ several mechanisms to survive within the vertebrate host, including evasion of the complement system. In this study, we examine the protection against human serum killing by the binding of host complement regulators C4b-binding protein (C4BP) and factor H (FH) to the bacterial surface of <i>B. burgdorferi</i>. Via serum depletion of isolated complement regulators, we found that the absence of C4BP did not alter the survival of <i>B. burgdorferi</i> strain B31; however, the removal of FH increased the sensitivity of this strain to human serum as previously described. The <i>B. garinii</i> seabird-isolated strain Far04, on the other hand, did not bind any complement regulators of human origin and was serum-sensitive, indicating its special host species specificity.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110977
Serena Salomè, Ida D'Acunzo, Federica Fanelli, Simona Perniciaro, Letizia Capasso, Francesco Raimondi, Chryssoula Tzialla, On Behalf Of The Study Group Of Neonatal Infectious Diseases
From 2020 to today, considerable knowledge on SARS-CoV-2 has been collected, even on pregnant women and their fetuses and newborns, and clinical guidelines have been written and implemented worldwide. Vaccination has considerably improved outcomes, but hesitancy amongst pregnant patients and the emergence of variants remain challenging, and SARS-CoV-2 positivity during pregnancy continues to be associated with an increased risk of maternal complications, premature delivery, and higher neonatal mortality and morbidity. A body of data now exists on the effect of SARS-CoV-2 during pregnancy on early neonatal outcomes, medical education in obstetrics and pediatrics, and longer-term developmental outcomes. This review aimed to present important findings on clinical outcomes and health recommendations for neonate born from a SARS-CoV-2-positive mother in order to summarize effective preventive healthcare guidelines.
{"title":"How to Manage a Neonate Born from a SARS-CoV-2-Positive Mother: A Narrative Review.","authors":"Serena Salomè, Ida D'Acunzo, Federica Fanelli, Simona Perniciaro, Letizia Capasso, Francesco Raimondi, Chryssoula Tzialla, On Behalf Of The Study Group Of Neonatal Infectious Diseases","doi":"10.3390/pathogens13110977","DOIUrl":"10.3390/pathogens13110977","url":null,"abstract":"<p><p>From 2020 to today, considerable knowledge on SARS-CoV-2 has been collected, even on pregnant women and their fetuses and newborns, and clinical guidelines have been written and implemented worldwide. Vaccination has considerably improved outcomes, but hesitancy amongst pregnant patients and the emergence of variants remain challenging, and SARS-CoV-2 positivity during pregnancy continues to be associated with an increased risk of maternal complications, premature delivery, and higher neonatal mortality and morbidity. A body of data now exists on the effect of SARS-CoV-2 during pregnancy on early neonatal outcomes, medical education in obstetrics and pediatrics, and longer-term developmental outcomes. This review aimed to present important findings on clinical outcomes and health recommendations for neonate born from a SARS-CoV-2-positive mother in order to summarize effective preventive healthcare guidelines.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.3390/pathogens13110979
Paweł Foksiński, Alicja Blank, Edyta Kaczorek-Łukowska, Joanna Małaczewska, Małgorzata Wróbel, Ewelina A Wójcik, Patrycja Sowińska, Nina Pietrzyk, Rafał Matusiak, Roman Wójcik
Background: Pseudomonas aeruginosa is a pathogen that causes infections in animals and humans, with veterinary implications including ear infections in dogs, respiratory diseases in cats, and mastitis in ruminants. In humans, it causes severe hospital-acquired infections, particularly in immunosuppressed patients. This study aimed to identify and assess the prevalence of specific virulence factors in Pseudomonas aeruginosa isolates.
Methods: We analyzed 98 Pseudomonas aeruginosa isolates from various animal samples (dogs, cats, ruminants, fowl) from northeastern Poland in 2019-2022 for virulence-related genes (toxA, exoU, exoT, exoS, lasB, plcN, plcH, pldA, aprA, gacA, algD, pelA, endA, and oprF) by PCR and assessed biofilm formation at 48 and 72 h. Genomic diversity was assessed by ERIC-PCR.
Results: The obtained results showed that all strains harbored the pelA gene (100%), while the lowest prevalence was found for pldA (24%) and exoU (36%). Regardless of the animal species, strong biofilm forming ability was prevalent among the strains after both 48 h (75%) and 72 h (74%). We obtained as many as 87 different genotyping profiles, where the dominant one was profile ERIC-48, observed in four strains.
Conclusions: No correlation was found between presence or absence of determined genes and the nature of infection. Similarly, no correlation was found between biofilm-forming genes and biofilm strength. The high genetic diversity indicates challenges for effective prevention, emphasizing the need for ongoing monitoring and research.
{"title":"Does Every Strain of <i>Pseudomonas aeruginosa</i> Attack the Same? Results of a Study of the Prevalence of Virulence Factors of Strains Obtained from Different Animal Species in Northeastern Poland.","authors":"Paweł Foksiński, Alicja Blank, Edyta Kaczorek-Łukowska, Joanna Małaczewska, Małgorzata Wróbel, Ewelina A Wójcik, Patrycja Sowińska, Nina Pietrzyk, Rafał Matusiak, Roman Wójcik","doi":"10.3390/pathogens13110979","DOIUrl":"10.3390/pathogens13110979","url":null,"abstract":"<p><strong>Background: </strong><i>Pseudomonas aeruginosa</i> is a pathogen that causes infections in animals and humans, with veterinary implications including ear infections in dogs, respiratory diseases in cats, and mastitis in ruminants. In humans, it causes severe hospital-acquired infections, particularly in immunosuppressed patients. This study aimed to identify and assess the prevalence of specific virulence factors in <i>Pseudomonas aeruginosa</i> isolates.</p><p><strong>Methods: </strong>We analyzed 98 <i>Pseudomonas aeruginosa</i> isolates from various animal samples (dogs, cats, ruminants, fowl) from northeastern Poland in 2019-2022 for virulence-related genes (toxA, exoU, exoT, exoS, lasB, plcN, plcH, pldA, aprA, gacA, algD, pelA, endA, and oprF) by PCR and assessed biofilm formation at 48 and 72 h. Genomic diversity was assessed by ERIC-PCR.</p><p><strong>Results: </strong>The obtained results showed that all strains harbored the <i>pel</i>A gene (100%), while the lowest prevalence was found for <i>pld</i>A (24%) and <i>exo</i>U (36%). Regardless of the animal species, strong biofilm forming ability was prevalent among the strains after both 48 h (75%) and 72 h (74%). We obtained as many as 87 different genotyping profiles, where the dominant one was profile ERIC-48, observed in four strains.</p><p><strong>Conclusions: </strong>No correlation was found between presence or absence of determined genes and the nature of infection. Similarly, no correlation was found between biofilm-forming genes and biofilm strength. The high genetic diversity indicates challenges for effective prevention, emphasizing the need for ongoing monitoring and research.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pseudomonas aeruginosa is causing increasing concern among clinicians due to its high mortality and resistance rates. This bacterium is responsible for various infections, especially in hospital settings, affecting some of the most vulnerable patients. Pseudomonas aeruginosa has developed resistance through multiple mechanisms, making treatment challenging. Diagnostic techniques are evolving, with rapid testing systems providing results within 4-6 h. New antimicrobial agents are continuously being developed, offering potential solutions to these complex clinical decisions. This article provides a review of the epidemiology, at-risk populations, resistance mechanisms, and diagnostic and treatment options for Pseudomonas aeruginosa.
{"title":"Multidrug Resistant <i>Pseudomonas aeruginosa</i> in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies.","authors":"Beth Schwartz, Katherine Klamer, Justin Zimmerman, Pramodini B Kale-Pradhan, Ashish Bhargava","doi":"10.3390/pathogens13110975","DOIUrl":"10.3390/pathogens13110975","url":null,"abstract":"<p><p><i>Pseudomonas aeruginosa</i> is causing increasing concern among clinicians due to its high mortality and resistance rates. This bacterium is responsible for various infections, especially in hospital settings, affecting some of the most vulnerable patients. <i>Pseudomonas aeruginosa</i> has developed resistance through multiple mechanisms, making treatment challenging. Diagnostic techniques are evolving, with rapid testing systems providing results within 4-6 h. New antimicrobial agents are continuously being developed, offering potential solutions to these complex clinical decisions. This article provides a review of the epidemiology, at-risk populations, resistance mechanisms, and diagnostic and treatment options for <i>Pseudomonas aeruginosa</i>.</p>","PeriodicalId":19758,"journal":{"name":"Pathogens","volume":"13 11","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}